Zecheus writes: Geron had won the first clinical trial of embryonic stem cell therapy in the United States, as previously reported in slashdot: http://science.slashdot.org/story/09/01/23/1647211/first-human-embryonic-stem-cell-study-approved, but is now ending that trial and divesting entirely from any research in the technology. This is an stunning turnaround for the company that holds pioneering patents and had developed more experimental drugs from the stem cell of human embryos than any other company in the world. “I deeply believe in the promise of stem cells,” John A. Scarlett, the chief executive of Geron said. However the move is widely seen as a major setback for the technology. (Maybe he meant the 'promise of adult stem cells' in which many therapies are already approved and in use.) Perhaps Geron bailed out because the clinical trial has only demonstrated a certain level of safety, but no improvement in the small number of patients; or to meet strategic/tactical business goals (i.e., to stay in business), In any case, it looks like the promise of embyronic stem cell therapies are overhyped and false.